ECC 2015 | Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC

Giorgio Scagliotti

At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

Share this video  
Similar topics
Related videos
2:03
TKIs to treat EGFRm-positive NSCLC
Marina Garassino
1:16
The promise of stereotactic radiotherapy for oligometastases
Françoise Mornex
1:50
Prof. Kelly’s overview of the RECaN project
Daniel Kelly
1:03
Managing oligometastatic NSCLC with thoracic irradiation
Françoise Mornex
2:06
Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro
Lung Cancer
Docetaxel, Ramucirumab
ECC 2015
Interview
26th September 2015
More from Giorgio Scagliotti
Phase 2 trial of chemotherapy plus gefitinib as first-line treatment for lung adenocarcinoma
Immunotherapy in NSCLC: a perspective
Future steps in translational medicine for early to late stage lung cancer
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals